HA Medicine: Wholly-owned subsidiary signs "Technology Transfer Agreement"

Hainan Haiyao Co., Ltd. announced that its wholly-owned subsidiary, Hainan Haiyao Group Biotechnology Co., Ltd., signed a "Technology Transfer Agreement" with Shanghai Bozhiyan New Drug Research Co., Ltd., to purchase the clinical batch approval for Dapoxetine tablets and to cooperate on its subsequent development, listing, and other matters. The total amount of the contract is estimated to be 44.8 million yuan, with funding from Haiyao Biotechnology's own funds. The transaction does not constitute a related party transaction or a major asset restructuring, and does not require approval by the shareholders' meeting.